Highlights and Quick Summary
- EPS Growth (basic) for the quarter ending September 29, 2021 was 3.92% (a -106.97% decrease compared to previous quarter)
- Year-over-year quarterly EPS Growth (basic) decreased by -93.48%
- Annual EPS Growth (basic) for 2020 was 62.4% (a -100.3% decrease from previous year)
- Twelve month EPS Growth (basic) ending September 29, 2021 was 27.56% (a -59.83% decrease compared to previous quarter)
Trailing EPS Growth (basic) for the last four month:
|29 Sep '21||29 Jun '21||—||—|
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical EPS Growth (basic) of Phathom Pharmaceuticals, Inc.Most recent EPS Growth (basic)of PHAT including historical data for past 10 years.
Interactive Chart of EPS Growth (basic) of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. EPS Growth (basic) for the past 10 Years (both Annual and Quarterly)
Business Profile of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.